Edson Crusca

Dr. Edson Crusca

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Luis Guilherme Mansor BassoLuis Guilherme Mansor Basso
Luis Guilherme Mansor Basso
Eduardo Festozo VicenteEduardo Festozo Vicente
Eduardo Festozo Vicente
ECEdson Crusca
Edson Crusca
ECEduardo M. Cilli
Eduardo M. Cilli
ACAntonio Costa-Filho
Antonio Costa-Filho
Viral membrane fusion is an orchestrated process triggered by membrane-anchored viral fusion glycoproteins. The S2 subunit of the spike glycoprotein from severe acute respiratory syndrome (SARS) coronavirus (CoV) contains internal domains called fusion peptides (FP) that play essential roles in virus entry. Although membrane fusion has been broadly studied, there are still major gaps in the molecular details of lipid rearrangements in the bilayer during fusion peptide-membrane interactions. Here we employed differential scanning calorimetry (DSC) and electron spin resonance (ESR) to gather information on the membrane fusion mechanism promoted by two putative SARS FPs. DSC data showed the peptides strongly perturb the structural integrity of anionic vesicles and support the hypothesis that the peptides generate opposing curvature stresses on phosphatidylethanolamine membranes. ESR showed that both FPs increase lipid packing and head group ordering as well as reduce the intramembrane water content for anionic membranes. Therefore, bending moment in the bilayer could be generated, promoting negative curvature. The significance of the ordering effect, membrane dehydration, changes in the curvature properties and the possible role of negatively charged phospholipids in helping to overcome the high kinetic barrier involved in the different stages of the SARS-CoV-mediated membrane fusion are discussed.

1 February 2009 in Peptides
Verified
Journal Article
Closed access
Mariana CastroMariana Castro
Mariana Castro
TFTânia Cristina G. Ferreira
Tânia Cristina G. Ferreira
Eduardo CilliEduardo Cilli
Eduardo Cilli
ECEdson Crusca
Edson Crusca
Maria José Soares Mendes GianniniMaria José Soares Mendes Giannini
Maria José Soares Mendes Giannini
WFWagner Fontes
Wagner Fontes

20 January 2011 in Peptide Science
Verified
Journal Article
Closed access
PDF file
ECEdson Crusca
Edson Crusca
ARAdrielle A. Rezende
Adrielle A. Rezende
RMReinaldo Marchetto
Reinaldo Marchetto
Maria José Soares Mendes GianniniMaria José Soares Mendes Giannini
Maria José Soares Mendes Giannini
WFWagner Fontes
Wagner Fontes
Eduardo CilliEduardo Cilli
Eduardo Cilli

1 November 2020 in Journal of Dentistry
Verified
Journal Article
Closed access
TCThamyris Carvalho
Thamyris Carvalho
TATamara Teodoro Araújo
Tamara Teodoro Araújo
TVTalita Mendes Oliveira Ventura
Talita Mendes Oliveira Ventura
ADAline Dionizio
Aline Dionizio
JCJoão Victor Câmara
João Victor Câmara
Marilia BuzalafMarilia Buzalaf
Marilia Buzalaf

1 April 2021 in Journal of Dentistry
Verified
Journal Article
Closed access
VPVinícius Taioqui Pelá
Vinícius Taioqui Pelá
Marilia BuzalafMarilia Buzalaf
Marilia Buzalaf
SNSamira Helena Niemeyer
Samira Helena Niemeyer
TBTommy Baumann
Tommy Baumann
FHFlavio Henrique-Silva
Flavio Henrique-Silva
TCThiago Saads Carvalho
Thiago Saads Carvalho

1 February 2021 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
BSBeatriz Cristina Pecoraro Sanches
Beatriz Cristina Pecoraro Sanches
CRCamila Aguiar Rocha
Camila Aguiar Rocha
JBJose Gregorio Martin Bedoya
Jose Gregorio Martin Bedoya
VSVinicius Luiz da Silva
Vinicius Luiz da Silva
PSPatricia Bento Da Silva
Patricia Bento Da Silva
RMReinaldo Marchetto
Reinaldo Marchetto
Background: Antimicrobial resistance poses substantial risks to human health. Thus, there is an urgent need for novel antimicrobial agents, including alternative compounds, such as peptides derived from bacterial toxin-antitoxin (TA) systems. ParELC3 is a synthetic peptide derived from the ParE toxin reported to be a good inhibitor of bacterial topoisomerases and is therefore a potential antibacterial agent. However, ParELC3 is inactive against bacteria due to its inability to cross the bacterial membranes. To circumvent this limitation we prepared and used rhamnolipid-based liposomes to carry and facilitate the passage of ParELC3 through the bacterial membrane to reach its intracellular target - the topoisomerases. Methods and Results: Small unilamellar liposome vesicles were prepared by sonication from three formulations that included 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and cholesterol. ParELC3 was loaded with high efficiency into the liposomes. Characterization by DLS and TEM revealed the appropriate size, zeta potential, polydispersity index, and morphology. In vitro microbiological experiments showed that ParELC3 loaded-liposomes are more efficient (29 to 11 μmol·L− 1) compared to the free peptide (> 100 μmol·L− 1) at inhibiting the growth of standard E. coli and S. aureus strains. RL liposomes showed high hemolytic activity but when prepared with POPC and Chol this activity had a significant reduction. Independently of the formulation, the vesicles had no detectable cytotoxicity to HepG2 cells, even at the highest concentrations tested (1.3 mmol·L− 1 and 50 μmol·L− 1 for rhamnolipid and ParELC3, respectively). Conclusion: The present findings suggest the potential use of rhamnolipid-based liposomes as nanocarrier systems to enhance the bioactivity of peptides.